TWI366464B - Cyclodextrin-based polymers for therapeutics delivery - Google Patents
Cyclodextrin-based polymers for therapeutics deliveryInfo
- Publication number
- TWI366464B TWI366464B TW092124615A TW92124615A TWI366464B TW I366464 B TWI366464 B TW I366464B TW 092124615 A TW092124615 A TW 092124615A TW 92124615 A TW92124615 A TW 92124615A TW I366464 B TWI366464 B TW I366464B
- Authority
- TW
- Taiwan
- Prior art keywords
- therapeutic
- cyclodextrin
- methods
- relates
- small molecule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/44—Polyester-amides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40885502P | 2002-09-06 | 2002-09-06 | |
US42283002P | 2002-10-31 | 2002-10-31 | |
US45199803P | 2003-03-04 | 2003-03-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200423947A TW200423947A (en) | 2004-11-16 |
TWI366464B true TWI366464B (en) | 2012-06-21 |
Family
ID=31982363
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092124615A TWI366464B (en) | 2002-09-06 | 2003-09-05 | Cyclodextrin-based polymers for therapeutics delivery |
TW100146937A TWI422379B (zh) | 2002-09-06 | 2003-09-05 | 用於醫療輸送之以環糊精為基礎之聚合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100146937A TWI422379B (zh) | 2002-09-06 | 2003-09-05 | 用於醫療輸送之以環糊精為基礎之聚合物 |
Country Status (17)
Families Citing this family (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
EP1534269B1 (en) | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
EP2277551B1 (en) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
BR0315198A (pt) * | 2002-10-09 | 2005-08-30 | Insert Therapeutics Inc | Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos |
SG129240A1 (en) * | 2003-01-23 | 2007-02-26 | Agency Science Tech & Res | Biodegradable copolymer and nucleic acid delivery system |
JP4009721B2 (ja) * | 2003-05-23 | 2007-11-21 | 独立行政法人産業技術総合研究所 | イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法 |
JP5537763B2 (ja) * | 2003-09-05 | 2014-07-02 | ザ ジェネラル ホスピタル コーポレイション | 放出システムとしてのポリアセタール薬物抱合体 |
US6960300B2 (en) * | 2003-09-08 | 2005-11-01 | Sami Labs Limited | Process for preparing water soluble diterpenes and their applications |
PL1675622T3 (pl) * | 2003-09-17 | 2017-11-30 | Nektar Therapeutics | Proleki na bazie wieloramiennego polimeru |
US8394365B2 (en) * | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
EP1742962B1 (en) * | 2004-04-23 | 2016-11-23 | Expedeon Limited | Methods and kits for folding proteins in the presence of linear or branched sugar polymers |
US8128954B2 (en) | 2004-06-07 | 2012-03-06 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
JP5107716B2 (ja) | 2004-11-05 | 2012-12-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 分子治療用生分解性リンカー |
TW200640493A (en) * | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
US7427605B2 (en) | 2005-03-31 | 2008-09-23 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
PE20070100A1 (es) * | 2005-06-22 | 2007-03-10 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO MODULADORES DE QUINASAS |
US20070021380A1 (en) * | 2005-07-22 | 2007-01-25 | Leonard Wiebe | Novel drug delivery compositions |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
JP2009509932A (ja) * | 2005-09-07 | 2009-03-12 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
TW200800872A (en) * | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
NZ567162A (en) * | 2005-09-07 | 2011-06-30 | Plexxikon Inc | 1, 3-disubstituted indole derivatives for use as PPAR modulators |
AU2006327551A1 (en) * | 2005-12-19 | 2007-06-28 | Capsutech Ltd. | Cyclodextrin-containing polymers and uses thereof |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
WO2007117981A2 (en) | 2006-03-29 | 2007-10-18 | Novartis Ag | Selective hydroxamate based mmp inhibitors |
US20080027212A1 (en) | 2006-06-28 | 2008-01-31 | Skinner Keith K | Methods and compositions for improved uptake of biological molecules |
US20090286790A1 (en) | 2006-07-20 | 2009-11-19 | Hidetomo Imase | Organic compounds |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US8354549B2 (en) * | 2006-11-30 | 2013-01-15 | Nektar Therapeutics | Method for preparing a polymer conjugate |
TW201509433A (zh) * | 2006-12-13 | 2015-03-16 | Cerulean Pharma Inc | 用於醫物傳遞之以環糊精為基之聚合物 |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
JP2010514695A (ja) | 2006-12-21 | 2010-05-06 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物および方法およびそのための適応症 |
JP2010516625A (ja) * | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
EP2109448B1 (en) * | 2007-02-09 | 2013-09-11 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
EP2489372A3 (en) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
CA2690943A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TW200918099A (en) * | 2007-09-14 | 2009-05-01 | Nitto Denko Corp | Drug carriers |
JP5597396B2 (ja) * | 2007-09-28 | 2014-10-01 | ナノデックス株式会社 | 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 |
WO2009052454A2 (en) | 2007-10-19 | 2009-04-23 | University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
AU2008324243B2 (en) | 2007-11-05 | 2012-03-08 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
PL2404901T3 (pl) | 2007-12-03 | 2013-10-31 | Novartis Ag | 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
CA2719457C (en) | 2008-03-24 | 2017-05-02 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
EP2269072B1 (en) | 2008-03-31 | 2017-08-23 | Boston Medical Center Corporation | Predictive marker for topoisomerase i inhibitors |
AU2009232355A1 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
CN104530052A (zh) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
US8110576B2 (en) * | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
US8557292B2 (en) | 2008-08-13 | 2013-10-15 | California Institute Of Technology | Carrier nanoparticles and related compositions, methods and systems |
US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
US20100068278A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-associations |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
CN102164617A (zh) | 2008-09-23 | 2011-08-24 | 尼克塔治疗公司 | 在受试者体内实现持续的治疗药物浓度的组合物和方法 |
BRPI0919842A8 (pt) * | 2008-10-21 | 2015-09-22 | Enzon Pharmaceuticals Inc | tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina |
EP2359852A4 (en) * | 2008-11-17 | 2015-05-20 | Nat Cancer Ct | NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND |
WO2010068759A1 (en) * | 2008-12-10 | 2010-06-17 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
EP2401225B1 (en) | 2009-02-26 | 2014-10-22 | The Regents of The University of California | A supramolecular approach for preparation of size controllable nanoparticles |
RU2011141123A (ru) | 2009-03-11 | 2013-04-20 | Плексксикон, Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ |
JP2012520311A (ja) * | 2009-03-11 | 2012-09-06 | プレキシコン インコーポレーテッド | Rafキナーゼの阻害のためのピロロ[2,3−b]ピリジン誘導体 |
MX2011008303A (es) * | 2009-04-03 | 2011-11-29 | Plexxikon Inc | Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas. |
TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20120077774A1 (en) | 2009-05-28 | 2012-03-29 | Cornell University | Compositions and their use for removing cholesterol |
JP5747432B2 (ja) * | 2009-05-28 | 2015-07-15 | 国立大学法人秋田大学 | 2置換修飾シクロデキストリンおよびこれを用いた核酸検出方法 |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
US20110152512A1 (en) * | 2009-09-09 | 2011-06-23 | John Ryan | Cyclodextrin-based polymers for therapeutics delivery |
AU2010295646B2 (en) | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
US8460745B2 (en) * | 2009-09-20 | 2013-06-11 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
AU2010315126B2 (en) | 2009-11-06 | 2015-06-25 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN102740698A (zh) | 2009-11-18 | 2012-10-17 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
US20110237540A1 (en) * | 2009-11-23 | 2011-09-29 | Crawford Thomas C | Cyclodextrin-based polymers for therapeutic delivery |
MX2012007429A (es) * | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma. |
US20120004195A1 (en) * | 2010-01-19 | 2012-01-05 | Alexandra Glucksmann | Cyclodextrin-based polymers for therapeutic delivery |
US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
JP2011190341A (ja) * | 2010-03-15 | 2011-09-29 | Nano Dex Kk | シクロデキストリン化合物 |
US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012044832A1 (en) * | 2010-09-30 | 2012-04-05 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
PT3590949T (pt) | 2010-10-01 | 2022-08-02 | Modernatx Inc | Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
US9233163B2 (en) | 2010-12-28 | 2016-01-12 | The Children's Hospital Of Philadelphia | Hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
WO2012103182A1 (en) | 2011-01-28 | 2012-08-02 | Cerulean Pharma Inc. | Method for fabricating nanoparticles |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US20120302505A1 (en) * | 2011-04-21 | 2012-11-29 | Fetzer Oliver S | Cyclodextrin-based polymers for therapeutic delivery |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
JP2015505559A (ja) * | 2012-01-31 | 2015-02-23 | セルリアン・ファーマ・インコーポレイテッド | 治療剤送達のためのシクロデキストリン系ポリマー |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20150051269A1 (en) * | 2012-03-13 | 2015-02-19 | Postech Academy-Industry Foundation | Drug Delivery Conjugate Capable of Controlled Release, and Use Thereof |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP3505176A1 (en) | 2012-04-02 | 2019-07-03 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9598503B2 (en) * | 2012-04-18 | 2017-03-21 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
WO2013170655A1 (en) | 2012-05-16 | 2013-11-21 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2014028209A1 (en) | 2012-08-14 | 2014-02-20 | The Trustees Of The University Of Pennsylvania | Stabilizing shear-thinning hydrogels |
EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
US11467158B2 (en) | 2012-10-29 | 2022-10-11 | Boston Medical Center Corporation | BRCA1 mutations as predictive markers for topoisomerase inhibitions |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2014093343A2 (en) * | 2012-12-10 | 2014-06-19 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
CN103044349B (zh) * | 2012-12-13 | 2014-05-21 | 浙江大学 | 一种微波辅助纳米铁酸盐制备乙二胺四乙酸酐的方法 |
CA2895239C (en) | 2012-12-21 | 2020-10-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6309980B2 (ja) * | 2013-02-25 | 2018-04-11 | ユニバーシティ オブ ロチェスター | 抗バイオフィルム剤を制御放出するためのナノ粒子及びその使用方法 |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US20140302516A1 (en) | 2013-03-14 | 2014-10-09 | University Of Washington Through Its Center For Commercialization | Polymer dot compositions and related methods |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
KR102244719B1 (ko) | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
EP3030902B1 (en) | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
JP2016534816A (ja) | 2013-11-01 | 2016-11-10 | レンスゲン、インコーポレイテッド | 2部分調節性眼内レンズデバイス |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2015179402A1 (en) * | 2014-05-19 | 2015-11-26 | North Carolina State University | Methods of folding a graft copolymer with dual anticancer drugs and related applications |
AU2015284236B2 (en) * | 2014-06-30 | 2018-03-08 | Tva (Abc), Llc | Targeted conjugates and particles and formulations thereof |
EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
CA2961356C (en) | 2014-09-15 | 2023-03-07 | Plexxikon Inc. | Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto |
CN104274837B (zh) * | 2014-09-18 | 2017-01-11 | 福格森(武汉)生物科技股份有限公司 | 一种尼洛替尼口服制剂 |
CN104311820B (zh) * | 2014-09-24 | 2017-06-20 | 北京化工大学 | 一种基于多糖接枝聚天冬氨酸苄酯构建可降解药物载体的方法 |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI547308B (zh) * | 2015-06-10 | 2016-09-01 | 聚和國際股份有限公司 | 聚電解質膠囊的製備方法及所製得的聚電解質膠囊 |
WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
WO2017006279A1 (en) * | 2015-07-08 | 2017-01-12 | Aten Porus Lifesciences | Cyclodextrin-polymer complexes and compostions and methods of making and using the same |
PT3324932T (pt) | 2015-07-22 | 2021-04-06 | Nitto Denko Corp | Composições e métodos para formas de liófilos de nanopartículas |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
KR20180033586A (ko) | 2015-08-04 | 2018-04-03 | 듀크 유니버시티 | 전달을 위한 유전적으로 인코딩된 내재적으로 무질서화된 스텔스 중합체 및 이의 이용 방법 |
AU2016328619B2 (en) | 2015-09-21 | 2020-07-16 | Opna Bio SA | Heterocyclic compounds and uses thereof |
AU2016343817B2 (en) | 2015-10-28 | 2021-05-27 | Tva (Abc), Llc | SSTR-targeted conjugates and particles and formulations thereof |
JP6900376B2 (ja) | 2015-12-01 | 2021-07-07 | レンスゲン、インコーポレイテッド | 調節式眼内レンズデバイス |
WO2017096361A1 (en) | 2015-12-04 | 2017-06-08 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
MX2018008888A (es) * | 2016-01-21 | 2019-06-13 | Aten Porus Lifesciences | Polimeros a base de ciclodextrina, metodos, composiciones y aplicaciones de los mismos. |
WO2017176807A2 (en) | 2016-04-04 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor |
WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
EP3512868A4 (en) | 2016-09-14 | 2020-04-15 | Duke University | NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
WO2018057847A1 (en) | 2016-09-23 | 2018-03-29 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
JP7366406B2 (ja) | 2017-01-03 | 2023-10-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 生分解性の抗菌性足場としての一酸化窒素放出性アルギン酸塩およびそれに関する方法 |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
CA3055474A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
WO2019006426A2 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | RAMIFIED MULTIFUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF |
US11319320B2 (en) | 2017-11-06 | 2022-05-03 | Snap Bio, Inc. | PIM kinase inhibitor compositions, methods, and uses thereof |
CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法,以及其适应症 |
US20210128734A1 (en) * | 2018-04-30 | 2021-05-06 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
EP3790899A1 (en) | 2018-05-09 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
WO2020037236A1 (en) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
EP3902841A4 (en) | 2018-12-28 | 2022-09-28 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING ANTIBACTERIAL POLYMERS AND SCAFFOLDS MADE THEREOF AND METHODS RELATED THEREOF |
US20220133692A1 (en) * | 2019-01-31 | 2022-05-05 | Northwestern University | Supramolecular photoprotection of a photosensitizer |
EP3953351A1 (en) | 2019-04-09 | 2022-02-16 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
CN114555610A (zh) | 2019-05-20 | 2022-05-27 | 麻省理工学院 | 硼酸酯前药及其用途 |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
US20210198239A1 (en) | 2019-12-06 | 2021-07-01 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
KR20210071296A (ko) * | 2019-12-06 | 2021-06-16 | (주) 에이치엔에이파마켐 | 공유결합성 유기 골격체 및 폴리머를 이용한 경피전달용 복합체 |
US20210220391A1 (en) | 2020-01-10 | 2021-07-22 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
CN111443068B (zh) * | 2020-03-06 | 2023-06-27 | 天津大学 | 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用 |
TW202204354A (zh) | 2020-04-02 | 2022-02-01 | 美商普雷辛肯公司 | 用於csk調節之化合物及方法以及其說明 |
US11807626B2 (en) | 2020-04-23 | 2023-11-07 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
EP4164658A1 (en) * | 2020-06-15 | 2023-04-19 | Nanosynthons LLC | Excipients providing stabilization and enhanced water solubilization and their uses |
US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
WO2022061251A1 (en) | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
CN112755197B (zh) * | 2020-10-09 | 2023-01-13 | 黑龙江大学 | 一种环糊精药物包合物及其制备方法和应用 |
WO2022159319A2 (en) * | 2021-01-19 | 2022-07-28 | Mountain Valley Md Inc | A porous aluminum nanoparticulate structure |
TW202241508A (zh) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
CN115160454A (zh) * | 2021-04-01 | 2022-10-11 | 四川大学 | 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法 |
CN113274541A (zh) * | 2021-05-10 | 2021-08-20 | 四川大学 | 一种抗菌型胶原基医用材料及其制备方法 |
KR20230050084A (ko) * | 2021-10-07 | 2023-04-14 | 주식회사 셀진 | Plga 및 약물을 함유하는 베타-사이클로덱스트린을 포함하는 약물 전달체 |
WO2023113479A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
CN114470237B (zh) * | 2022-03-21 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种类病毒结构基因载体、药物递送系统、其制备方法及其应用 |
CN115006549A (zh) * | 2022-06-16 | 2022-09-06 | 湖南科技大学 | 一种粒径可控及可控降解的酸敏型交联环糊精纳米水凝胶药物递送系统的制备方法 |
CN115340615B (zh) * | 2022-08-12 | 2023-05-02 | 同济大学 | 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用 |
Family Cites Families (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2131201A (en) | 1928-08-04 | 1938-09-27 | Gen Motors Corp | Composite clutch |
US2129408A (en) | 1936-07-02 | 1938-09-06 | Arthur C Davidson | Truck stabilizer |
US2129401A (en) | 1937-09-09 | 1938-09-06 | Botinger Fred | Flexible utility ladder |
US2131208A (en) | 1938-02-26 | 1938-09-27 | Union Switch & Signal Co | Remote indication apparatus |
US3472835A (en) * | 1964-02-12 | 1969-10-14 | American Mach & Foundry | Schardinger dextrins |
US3454530A (en) * | 1966-03-07 | 1969-07-08 | Leslie C Case | Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride |
US3453257A (en) * | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) * | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3654261A (en) * | 1968-06-27 | 1972-04-04 | Cpc International Inc | Quaternary ammonium alkoxide alkoxy polyol compounds |
USRE32268E (en) * | 1973-03-01 | 1986-10-21 | Strategic Medical Research Corp. | Therapeutic composition and method of therapeutically treating warm blooded animals therewith |
GB1390479A (en) | 1973-09-05 | 1975-04-16 | I Orch Sinteza Akademii Nauk L | Pharmaceutical composition for treatment of parkinsonism |
DE2843963A1 (de) | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
DE2842862A1 (de) * | 1978-10-02 | 1980-04-10 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten |
CA1190855A (en) | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
JPS58113198A (ja) * | 1981-12-26 | 1983-07-05 | Hidetoshi Tsuchida | シクロデキストリンが結合したポルフイリン化合物 |
US4570629A (en) | 1982-03-17 | 1986-02-18 | University Of Illinois Foundation | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same |
JPS58167613A (ja) | 1982-03-26 | 1983-10-03 | Mitsubishi Petrochem Co Ltd | 水溶性シクロデキストリン含有重合体の製造法 |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
CA1208558A (en) | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
DE3463211D1 (en) | 1983-07-01 | 1987-05-21 | Battelle Memorial Institute | Biodegradable polypeptide and its use in the sustained release of medicaments |
US4525495A (en) | 1983-07-22 | 1985-06-25 | The Dow Chemical Company | Mineral filled composites |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
CH663951A5 (fr) | 1984-10-10 | 1988-01-29 | Nestle Sa | Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant. |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
JPH0651725B2 (ja) * | 1985-02-28 | 1994-07-06 | メルシャン株式会社 | 部分メチル化シクロデキストリン及びその製造方法 |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4841081A (en) * | 1985-10-16 | 1989-06-20 | Osaka Soda Co., Ltd. | Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
ES2058081T3 (es) | 1986-09-05 | 1994-11-01 | American Cyanamid Co | Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos. |
GB2197720A (en) | 1986-11-20 | 1988-05-25 | Nat Res Dev | Immobilisation of polynucleotides |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
JP2993967B2 (ja) * | 1987-06-17 | 1999-12-27 | インスティテュート・フォー・チャイルド・ヘルス・リサーチ | ダニアレルゲンのクローニング |
US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
US4774329A (en) * | 1987-08-04 | 1988-09-27 | American Maize-Products Company | Controlled release agent for cetylpyridinium chloride |
US4941996A (en) | 1987-10-19 | 1990-07-17 | Minnesota Mining And Manufacturing Company | Inclusion complexes providing second harmonic generation |
US5760015A (en) | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
JP2614081B2 (ja) | 1988-05-27 | 1997-05-28 | 大塚化学株式会社 | 光学活性β−ラクタム誘導体の製造法 |
US4887778A (en) | 1988-06-01 | 1989-12-19 | Universal Instruments Corporation | Feeder drive assembly and replaceable section for tape supplying and cover peeling |
JPH01319502A (ja) * | 1988-06-21 | 1989-12-25 | Showa Denko Kk | シクロデキストリン誘導体及びその製造方法 |
HU200913B (en) | 1988-07-28 | 1990-09-28 | Ciklodextrin Kutato Fejlesztoe | Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility |
MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
US4902788A (en) | 1988-09-29 | 1990-02-20 | Uop | Crosslinked cyclodextrins supported on porous refractory inorganic oxides |
US5098793A (en) * | 1988-09-29 | 1992-03-24 | Uop | Cyclodextrin films on solid substrates |
IT1230566B (it) | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH03221505A (ja) | 1990-01-29 | 1991-09-30 | Toppan Printing Co Ltd | シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法 |
EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
DE4009825A1 (de) * | 1990-03-27 | 1991-10-02 | Consortium Elektrochem Ind | Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung |
US5139687A (en) | 1990-05-09 | 1992-08-18 | The Proctor & Gamble Company | Non-destructive carriers for cyclodextrin complexes |
JPH0425505A (ja) | 1990-05-21 | 1992-01-29 | Toppan Printing Co Ltd | シクロデキストリンポリマー及びシクロデキストリン膜の製造方法 |
US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
FR2665169A1 (fr) | 1990-07-30 | 1992-01-31 | Rhone Poulenc Chimie | Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres. |
JPH04106101A (ja) | 1990-08-27 | 1992-04-08 | Showa Denko Kk | シクロデキストリンポリマーおよびその製造方法 |
DE69103503T2 (de) * | 1990-09-28 | 1995-01-05 | Mercian Corp | Adriamycinderivate. |
JPH059205A (ja) * | 1990-09-28 | 1993-01-19 | Mercian Corp | 新規なアドリアマイシン誘導体 |
WO1992006127A1 (fr) | 1990-10-01 | 1992-04-16 | Toppan Printing Co., Ltd. | Polymere de cyclodextrine et film de cyclodextrine forme a partir de celui-ci |
CA2066633A1 (en) * | 1990-11-30 | 1992-05-31 | Masanobu Yoshinaga | Processes for producing cyclodextrin derivatives and polymers containing immobilizing cyclodextrin therein |
WO1992010092A1 (en) | 1990-12-06 | 1992-06-25 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5148854A (en) * | 1990-12-11 | 1992-09-22 | Toshiba Kikai Kabushiki Kaisha | Counting die cast manufactured goods |
NO180605C (no) * | 1990-12-19 | 2003-08-28 | Geco As | Anordning til vektbelastning av streamerkabel |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
KR940702517A (ko) | 1991-09-06 | 1994-08-20 | 죤 그레미 블레어 | 콜레스테롤 농도 저하용 조성물 및 방법 |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
US6849462B1 (en) * | 1991-11-22 | 2005-02-01 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
JP2976154B2 (ja) | 1991-11-27 | 1999-11-10 | コニカ株式会社 | ハロゲン化銀写真感光材料用固形処理剤 |
JP3221505B2 (ja) | 1992-02-06 | 2001-10-22 | 日本信号株式会社 | 移動体の運行管理装置 |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
JPH05331074A (ja) | 1992-05-27 | 1993-12-14 | Nippon Oil & Fats Co Ltd | 薬物運搬体 |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
IT1256134B (it) | 1992-09-09 | 1995-11-29 | Luigi Boltri | Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono |
US5482719A (en) | 1992-10-30 | 1996-01-09 | Guillet; James E. | Drug delivery systems |
ES2102186T3 (es) * | 1992-11-30 | 1997-07-16 | Ciba Geigy Ag | Esteres de hidratos de carbono polimerizables, polimeros de los mismos y su empleo. |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
EP0693924B2 (en) | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
HU210922B (en) | 1993-05-24 | 1995-09-28 | Europharmaceuticals Sa | Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
TW328535B (en) * | 1993-07-02 | 1998-03-21 | Novartis Ag | Functional photoinitiators and their manufacture |
JP3288149B2 (ja) | 1993-08-05 | 2002-06-04 | 日本食品化工株式会社 | シクロデキストリンポリマー及びその製造方法 |
RU2094059C1 (ru) | 1993-08-30 | 1997-10-27 | Московский государственный университет, химический факультет | Способ транспорта нейротропных препаратов в мозг |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5880154A (en) * | 1994-02-01 | 1999-03-09 | The Board Of Regents Of The University Of Nebraska | Polymeric adamantane analogues |
TW307775B (en) | 1994-02-15 | 1997-06-11 | Novartis Erfind Verwalt Gmbh | Unsaturated carbohydrate derivatives, polymers thereof and their use |
KR100357839B1 (ko) | 1994-03-07 | 2003-08-02 | 더 다우 케미칼 캄파니 | 생체활성및/또는표적화된덴드리머콘쥬게이트 |
JPH07316205A (ja) | 1994-03-30 | 1995-12-05 | D D S Kenkyusho:Kk | シクロデキストリン誘導体 |
HU218280B (en) | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
US6589736B1 (en) * | 1994-11-22 | 2003-07-08 | The Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
US5691316A (en) | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
US5716594A (en) * | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
US5549974A (en) * | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5679773A (en) * | 1995-01-17 | 1997-10-21 | Affymax Technologies N.V | Reagants and methods for immobilized polymer synthesis and display |
EP0776330B1 (en) * | 1994-06-23 | 2003-08-20 | Affymax Technologies N.V. | Photolabile compounds and methods for their use |
US5776842A (en) | 1994-06-23 | 1998-07-07 | Cellresin Technologies, Llc | Cellulosic web with a contaminant barrier or trap |
US5494854A (en) | 1994-08-17 | 1996-02-27 | Texas Instruments Incorporated | Enhancement in throughput and planarity during CMP using a dielectric stack containing HDP-SiO2 films |
JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
US5548932A (en) * | 1994-11-08 | 1996-08-27 | Maxcess Technologies, Inc. | Adjustable cable tray support system |
US6353055B1 (en) * | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
US5728804A (en) * | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
EA002400B1 (ru) | 1996-03-12 | 2002-04-25 | Пи Джи-Ти Экс Эл Компани, Л.П. | Водорастворимые пролекарства противоракового действия |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
JP3830198B2 (ja) | 1996-03-29 | 2006-10-04 | 東光薬品工業株式会社 | 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤 |
DE19612768A1 (de) | 1996-03-29 | 1997-10-02 | Basf Ag | Cyclodextringruppen enthaltende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung |
JPH11514388A (ja) * | 1996-04-03 | 1999-12-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | シクロデキストリン化合物ならびにその製造法および使用 |
DE19629494A1 (de) | 1996-07-09 | 1998-01-15 | Schering Ag | Pseudopolyrotaxane |
US5844030A (en) * | 1996-07-09 | 1998-12-01 | Andros; Nicholas | Charged ion cleaning devices and cleaning system |
US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
DE69720041T2 (de) | 1996-11-14 | 2004-01-08 | Affymetrix, Inc., Santa Clara | Chemische amplifizierung zur synthese von musterordnungen |
JPH10158195A (ja) | 1996-11-28 | 1998-06-16 | Res Inst For Prod Dev | 配位結合を利用した薬物−高分子複合体製剤の調製方法 |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
HUP9700632A3 (en) | 1997-03-24 | 1999-10-28 | Cyclolab Ciklodextrin Kutato F | Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same |
AU7124598A (en) | 1997-04-18 | 1998-11-13 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
EP1003555A1 (en) | 1997-04-23 | 2000-05-31 | The University of Otago | Controlled release of ophthalmic compositions |
WO1998049350A1 (en) | 1997-04-30 | 1998-11-05 | Regents Of The University Of Minnesota | In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
AU749032B2 (en) * | 1997-06-13 | 2002-06-20 | Johns Hopkins University, The | Therapeutic nanospheres |
DE19726186A1 (de) | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
JPH11100401A (ja) * | 1997-07-30 | 1999-04-13 | Kikkoman Corp | 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤 |
US6410342B1 (en) * | 1997-08-19 | 2002-06-25 | Pharmacopeia, Inc. | Method and apparatus for controlled photoelution |
CA2302316A1 (en) * | 1997-09-15 | 1999-03-25 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
EP1037649B1 (en) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
GB9801109D0 (en) | 1998-01-20 | 1998-03-18 | Pfizer | Cyclodextrin compositions |
EP2332645A1 (en) * | 1998-02-11 | 2011-06-15 | The University Of Houston | Apparatus for chemical and biochemical reactions using photo-generated reagents |
IT1298732B1 (it) | 1998-03-13 | 2000-02-02 | Recordati Chem Pharm | Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
WO1999061062A1 (en) | 1998-05-29 | 1999-12-02 | Massachusetts Institute Of Technology | Cyclodextrin complexes |
US6509323B1 (en) * | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
CA2346866A1 (en) | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
ATE356637T1 (de) | 1998-12-04 | 2007-04-15 | California Inst Of Techn | Supramolekulare komplexe enthaltende arzneimittel |
DE69930764D1 (de) | 1998-12-23 | 2006-05-18 | G D Searle Llc St Louis | Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia |
US6740643B2 (en) * | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
FR2789685B1 (fr) * | 1999-02-15 | 2001-05-04 | Univ Lille Sciences Tech | Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) |
AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
FR2792942B1 (fr) | 1999-04-29 | 2001-06-08 | Commissariat Energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
DK1102785T3 (da) | 1999-06-07 | 2013-05-13 | Arrowhead Res Corp | Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler |
WO2000075162A1 (en) | 1999-06-07 | 2000-12-14 | Mirus Corporation | A compound containing a labile disulfide bond |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US6420378B1 (en) | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
EP1233671A4 (en) | 1999-11-29 | 2005-11-02 | Mirus Corp | COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS |
SK282717B6 (sk) | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Spôsob prípravy ultravysokomolekulových hyalurónanov |
US20010041706A1 (en) | 2000-03-24 | 2001-11-15 | Synold Timothy W. | Blockade of taxane metabolism |
WO2001074401A2 (en) * | 2000-03-31 | 2001-10-11 | Supergen, Inc. | Camptothecin complexes |
JP2001288097A (ja) | 2000-04-07 | 2001-10-16 | Pg-Txl Co Lp | 水溶性パクリタキセル誘導体 |
AU2001270070B2 (en) | 2000-06-22 | 2006-03-16 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6664228B1 (en) | 2000-08-10 | 2003-12-16 | Ceramoptec Industries, Inc. | Photoselective marking of biological targets |
US6602707B2 (en) * | 2000-08-01 | 2003-08-05 | Oregon Health & Science University | Mammalian cell surface DNA receptor-encoding nucleic acid |
WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
WO2002057424A2 (en) | 2001-01-17 | 2002-07-25 | Zycos Inc. | Nucleic acid delivery formulations |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6828392B2 (en) | 2001-08-28 | 2004-12-07 | Carlsberg A/S | Hydroxy and amine functionalized resins |
WO2003020305A1 (en) | 2001-08-30 | 2003-03-13 | Baylor College Of Medecine | Methionine restriction for cancer therapy |
US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
EP1575976A4 (en) | 2001-11-02 | 2006-08-23 | Insert Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
US6527887B1 (en) * | 2002-01-18 | 2003-03-04 | Mach I, Inc. | Polymeric cyclodextrin nitrate esters |
AU2003239121A1 (en) * | 2002-02-22 | 2003-09-09 | Insert Therapeutics, Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7776814B2 (en) | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
AU2003265576A1 (en) | 2002-08-23 | 2004-03-11 | The Mclean Hospital Corporation | Corticosteroid conjugates and uses thereof |
AU2003256038A1 (en) | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
EP2277551B1 (en) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
US20040047835A1 (en) | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
CA2818071C (en) | 2002-09-06 | 2015-08-18 | Cerulean Pharma Inc. | Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery |
EP1551425A4 (en) | 2002-10-09 | 2006-09-20 | Kosan Biosciences Inc | THERAPEUTIC FORMULATIONS |
BR0315198A (pt) * | 2002-10-09 | 2005-08-30 | Insert Therapeutics Inc | Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos |
JP4745664B2 (ja) | 2002-10-31 | 2011-08-10 | 日本化薬株式会社 | カンプトテシン類の高分子誘導体 |
EP2213738B1 (en) | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
WO2004052315A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI405573B (zh) | 2003-01-27 | 2013-08-21 | Endocyte Inc | 維生素-受體結合性藥物輸送共軛物中間物及製備方法 |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
CN1216057C (zh) | 2003-03-28 | 2005-08-24 | 贵州省生物研究所 | 喜树碱类似物的衍生物及其制备方法 |
CN101274098A (zh) | 2003-05-30 | 2008-10-01 | 健泰科生物技术公司 | 利用抗-vegf抗体的治疗 |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
WO2006004574A2 (en) | 2004-02-19 | 2006-01-12 | Abbott Laboratories | Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
JP2008504809A (ja) | 2004-06-04 | 2008-02-21 | ジェネンテック・インコーポレーテッド | Egfr突然変異 |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
MX2007007212A (es) | 2004-12-15 | 2007-11-07 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento del cancer. |
TW200640493A (en) | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
PL1853250T3 (pl) | 2005-02-18 | 2012-03-30 | Abraxis Bioscience Llc | Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona |
CA2598441A1 (en) | 2005-02-24 | 2006-08-31 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
US7427605B2 (en) | 2005-03-31 | 2008-09-23 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
JP2008546421A (ja) | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Egfrおよびkras変異 |
JP4994618B2 (ja) | 2005-08-11 | 2012-08-08 | 学校法人北里研究所 | Ts−1/カンプトテシン類による化学放射線療法 |
US8143236B2 (en) | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
EP1996612A4 (en) | 2006-03-03 | 2010-10-20 | Univ Kingston | COMPOSITIONS FOR THE TREATMENT OF CANCER |
KR100917809B1 (ko) | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
TW201509433A (zh) | 2006-12-13 | 2015-03-16 | Cerulean Pharma Inc | 用於醫物傳遞之以環糊精為基之聚合物 |
JP2010516625A (ja) * | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20110177161A1 (en) | 2007-05-24 | 2011-07-21 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin |
FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
WO2009079452A2 (en) | 2007-12-14 | 2009-06-25 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of hiv infection |
AU2009232355A1 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
US20100056555A1 (en) | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
BRPI1014854A2 (pt) | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
US20120114658A1 (en) | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
US20110245201A1 (en) | 2009-09-15 | 2011-10-06 | John Ryan | Treatment of cancer |
US20130029909A1 (en) | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
AU2010295646B2 (en) | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
US20110237540A1 (en) | 2009-11-23 | 2011-09-29 | Crawford Thomas C | Cyclodextrin-based polymers for therapeutic delivery |
US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
DK2525830T3 (en) | 2010-01-22 | 2016-08-15 | Ascendis Pharma As | DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
WO2012044832A1 (en) | 2010-09-30 | 2012-04-05 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
WO2013037789A1 (en) | 2011-09-12 | 2013-03-21 | Universiteit Gent | Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer |
WO2013059651A1 (en) | 2011-10-21 | 2013-04-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bifunctional compounds |
WO2014055913A1 (en) | 2012-10-05 | 2014-04-10 | Cerulean Pharma Inc. | Treatment of cancer |
-
2003
- 2003-09-04 EP EP10184884.4A patent/EP2277551B1/en not_active Expired - Lifetime
- 2003-09-04 EP EP10184901.6A patent/EP2402036B1/en not_active Expired - Lifetime
- 2003-09-04 ES ES10184884T patent/ES2417324T3/es not_active Expired - Lifetime
- 2003-09-04 PT PT03770286T patent/PT1534340E/pt unknown
- 2003-09-04 KR KR1020167024300A patent/KR101857900B1/ko active IP Right Grant
- 2003-09-04 KR KR1020177037716A patent/KR102008768B1/ko active IP Right Grant
- 2003-09-04 EP EP03770286A patent/EP1534340B1/en not_active Expired - Lifetime
- 2003-09-04 ES ES03770286T patent/ES2377318T3/es not_active Expired - Lifetime
- 2003-09-04 CN CN201110329366.XA patent/CN102516417B/zh not_active Expired - Lifetime
- 2003-09-04 KR KR1020137006800A patent/KR101476067B1/ko active IP Right Grant
- 2003-09-04 MX MX2013004590A patent/MX367615B/es unknown
- 2003-09-04 AT AT03770286T patent/ATE533513T1/de active
- 2003-09-04 AU AU2003278764A patent/AU2003278764C1/en not_active Expired
- 2003-09-04 BR BR122012021252A patent/BR122012021252B8/pt active IP Right Grant
- 2003-09-04 ES ES10184901.6T patent/ES2666694T3/es not_active Expired - Lifetime
- 2003-09-04 BR BRPI0314042A patent/BRPI0314042B8/pt active IP Right Grant
- 2003-09-04 PT PT101848844T patent/PT2277551E/pt unknown
- 2003-09-04 EP EP17209803.0A patent/EP3332811A1/en active Pending
- 2003-09-04 MX MXPA05002444A patent/MXPA05002444A/es active IP Right Grant
- 2003-09-04 CN CN201410658743.8A patent/CN104383554B/zh not_active Expired - Lifetime
- 2003-09-04 WO PCT/US2003/027588 patent/WO2004022099A2/en active Application Filing
- 2003-09-04 KR KR1020127020305A patent/KR20120104412A/ko not_active IP Right Cessation
- 2003-09-04 JP JP2004569982A patent/JP2006502301A/ja not_active Withdrawn
- 2003-09-04 CA CA2497792A patent/CA2497792C/en not_active Expired - Lifetime
- 2003-09-04 KR KR1020147014132A patent/KR20140070676A/ko active Search and Examination
- 2003-09-04 KR KR1020057003918A patent/KR101268258B1/ko active IP Right Review Request
- 2003-09-05 TW TW092124615A patent/TWI366464B/zh not_active IP Right Cessation
- 2003-09-05 US US10/656,838 patent/US7270808B2/en active Active
- 2003-09-05 TW TW100146937A patent/TWI422379B/zh not_active IP Right Cessation
-
2005
- 2005-06-15 HK HK11105534.9A patent/HK1151467A1/xx not_active IP Right Cessation
- 2005-06-15 HK HK05104980.9A patent/HK1072202A1/xx not_active IP Right Cessation
-
2007
- 2007-07-25 US US11/881,325 patent/US8110179B2/en active Active
-
2009
- 2009-12-24 AU AU2009251190A patent/AU2009251190C1/en not_active Expired
-
2011
- 2011-01-06 JP JP2011001566A patent/JP5586487B2/ja not_active Expired - Lifetime
- 2011-10-20 US US13/277,780 patent/US8314230B2/en not_active Expired - Lifetime
-
2012
- 2012-01-12 JP JP2012004159A patent/JP5681646B2/ja not_active Expired - Lifetime
- 2012-02-16 CY CY20121100157T patent/CY1112362T1/el unknown
- 2012-03-15 US US13/421,839 patent/US8252276B2/en not_active Expired - Lifetime
- 2012-07-19 US US13/553,400 patent/US8389499B2/en not_active Expired - Lifetime
- 2012-07-19 US US13/553,376 patent/US8399431B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,294 patent/US8680202B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,243 patent/US8475781B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,283 patent/US8404662B2/en not_active Expired - Lifetime
-
2013
- 2013-01-11 US US13/739,896 patent/US8609081B2/en not_active Expired - Lifetime
- 2013-01-11 US US13/739,881 patent/US8580242B2/en not_active Expired - Lifetime
- 2013-01-11 US US13/739,864 patent/US8518388B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,019 patent/US8580243B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,052 patent/US8580244B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,076 patent/US8603454B2/en not_active Expired - Lifetime
- 2013-07-31 CY CY20131100656T patent/CY1114941T1/el unknown
- 2013-10-17 US US14/056,554 patent/US20140044669A1/en not_active Abandoned
- 2013-10-24 US US14/061,868 patent/US9550860B2/en not_active Expired - Lifetime
-
2014
- 2014-05-27 JP JP2014108845A patent/JP5934743B2/ja not_active Expired - Lifetime
- 2014-07-21 US US14/336,495 patent/US20150165055A1/en not_active Abandoned
- 2014-09-18 IL IL234716A patent/IL234716A0/en unknown
- 2014-09-18 IL IL234715A patent/IL234715A0/en unknown
-
2017
- 2017-03-07 US US15/451,861 patent/US20170369651A1/en not_active Abandoned
-
2018
- 2018-10-23 HK HK18113565.8A patent/HK1254600A1/zh unknown
-
2021
- 2021-01-08 US US17/144,598 patent/US20210128516A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254600A1 (zh) | 用於輸送與其共價結合喜樹鹼的基於環糊精的聚合物 | |
TW200640493A (en) | Cyclodextrin-based polymers for therapeutics delivery | |
WO2008076333A8 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
ATE342054T1 (de) | Verfahren und zusammansetzung zur behandlung von krebs | |
WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
MA32394B1 (fr) | Composes pegyles d'insuline lispro | |
ATE532790T1 (de) | Einschlussverbindung mit cucurbiturilderivaten als wirtsmolekül, und diese enthaltende pharmazeutische zusammensetzung | |
PT1560854E (pt) | Taxanos ligados covalentemente ao ácido hialurónico ou a derivados do ácido hialurónico | |
WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
HK1084941A1 (en) | Compounds and their use | |
WO2007004067A3 (en) | Methods and compositions for the delivery of biologically active agents | |
WO2007064345A3 (en) | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | |
UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
IL188774A0 (en) | Compositions for delivery of drug combinations | |
TW200738658A (en) | Novel compounds | |
ATE456379T1 (de) | Verbindung aus hydrophilem polymer und polycarboxyloligopeptid und arzneimittel, die obige verbindung enthaltender medizinischer verbund und verwendung der obigen verbindung in arzneimitteln | |
TW200740781A (en) | Novel compounds | |
WO2007005056A3 (en) | Platinum complexes with mononitrile-containing ligands | |
EA201070193A1 (ru) | Лечение детских опухолей | |
TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | |
GB0317491D0 (en) | Organic compounds | |
WO2004091542A3 (en) | Nitrogen containing integrin targeting compounds | |
CY1116049T1 (el) | Πολυπεπτιδια απροτινινης για την μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |